BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.
Bibliography:
1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715
2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933
3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015
